BlaSHV genes in Klebsiella pneumoniae: Different allele distributions are associated with different promoters within individual isolates by Hammond, David S. et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2005, p. 256–263 Vol. 49, No. 1
0066-4804/05/$08.000 doi:10.1128/AAC.49.1.256–263.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
blaSHV Genes in Klebsiella pneumoniae: Different Allele Distributions
Are Associated with Different Promoters within Individual Isolates
David S. Hammond,1 Jacqueline M. Schooneveldt,2 Graeme R. Nimmo,2 Flavia Huygens,1
and Philip M. Giffard1*
Cooperative Research Centre for Diagnostics, Queensland University of Technology,1 and Queensland Health
Pathology Services, Microbiology Department, Princess Alexandra Hospital,2 Brisbane, Australia
Received 1 May 2004/Returned for modification 26 July 2004/Accepted 26 September 2004
Extended-spectrum -lactamases (ESBLs) emerge by point mutation from non-extended-spectrum precur-
sors. The aims of this study were to reveal the basis for variations in resistance levels found in a collection of
21 Klebsiella pneumoniae clinical isolates from Brisbane, Australia. Previous studies have shown that 20 of these
isolates possess blaSHV-11, blaSHV-2a, and/or blaSHV-12, and there is an association between the copy numbers of
the ESBL-encoding genes and resistance levels. In this study, a real-time PCR method for interrogating the
polymorphic sites at codons 238 and 240 was developed, and this confirmed the relationship between mutant
gene copy numbers and resistance levels. The blaSHV promoter region was cloned from one of the ESBL-
expressing isolates, and this showed that blaSHV genes exist downstream of two different promoters within this
single isolate. These promoters have both been reported previously, and they differ by virtue of the presence or
absence of an IS26 insertion. The blaSHV copy numbers in cis with the different promoters were measured, and
the copy number of the IS26 promoter was correlated with resistance levels. Cloning and analysis of PCR
products showed that different blaSHV variants existed in cis with individual promoters in individual isolates
but that mutant genes were more abundant downstream of the IS26 promoter. There were no ESBL-positive
isolates without this promoter. It was concluded that blaSHV in cis with the IS26 promoter is located on an
amplifiable replicon, and the presence of the IS26 insertion may facilitate the acquisition of an ESBL-positive
phenotype.
SHV -lactamases are prevalent in gram-negative bacteria
(2). SHV-1 can hydrolyze penicillin and cephalosporins but not
expanded-spectrum antibiotics such as oxyimino cephalospo-
rins and monobactams. The introduction and widespread use
of expanded-spectrum antibiotics has led to the appearance of
extended spectrum -lactamases (ESBLs) which are able to
hydrolyze these compounds (1).
Numerous variants of the SHV and TEM enzymes have
been reported (www.lahey.org/studies/webt.stm). Variation is
exclusively in the form of amino acid substitutions (11, 13).
Jacoby (7) has assembled data from studies on the effects of
substitutions on activity. It appears that conversion of a non-
ESBL SHV enzyme to an ESBL is nearly always caused by a
G238S substitution, while a further extension of spectrum and
increased enzyme activity can be conferred by an E240K sub-
stitution. Although many other substitutions have been re-
ported, it appears that for the SHV family sites 238 and 240 are
the most important for acquiring ESBL activity.
Previously, we have reported the study of a collection of 21
Klebsiella pneumoniae isolates that included 13 isolates that
expressed SHV ESBLs (6). The SHV -lactamase genes iden-
tified in this collection encoded SHV-1 and SHV-11 (non-
ESBL), SHV-2a (ESBL with a G238S mutation), and SHV-12
(ESBL with G238S and E240K mutations). SHV-11, SHV-2a,
and SHV-12 differ from SHV-1, SHV-2, and SHV-5, respec-
tively, at codon 35, where there is an L35Q substitution. Lim-
ited cloning of PCR products and isoelectric focusing sug-
gested that most if not all of the isolates contain multiple SHV
-lactamase-encoding genes. A single-base extension method
for interrogating the polymorphic sites in codons 238 and 240
was developed, and this revealed a strong correlation between
the level of resistance to expanded-spectrum -lactam antibi-
otics and the relative copy numbers of the different blaSHV
alleles (6).
The coexistence of different blaSHV alleles within individual
isolates is of considerable practical significance because, as has
been noted by others (3, 12, 19), it raises questions about the
validity of surveys in which blaSHV genes are amplified from
genome extracts and the primary PCR product is identified by
sequencing. Genes with both the codon 238 and codon 240
mutations would be expected to be dominant (as opposed to
recessive) over single-mutation or unmutated genes with re-
spect to resistance to expanded spectrum -lactams. It is easy
to envisage a situation in which an ESBL-encoding mutant
gene is in a small minority in comparison to a non-ESBL-
encoding homolog and yet confers the clinically relevant resis-
tance phenotype. Therefore, the first part of this study was
designed to confirm the results of the minisequencing-based
allele copy number measurements by using a newly developed
real-time PCR assay for allele copy number ratios and also by
carrying out extensive cloning and sequencing of blaSHV-de-
rived PCR products. In the second part of this study, we char-
acterized the blaSHV promoters and investigated whether dif-
ferent promoters could coexist in single isolates, whether
homologous recombination equilibrates blaSHV across differ-
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ent replicons, which promoters are associated with copy num-
ber variation, and whether our results are consistent with pre-
vious studies of the epidemiology of the SHV-11,2a,12 family.
In the course of this work we developed a suite of real-time
PCR-based methods for directly determining blaSHV copy
numbers, and these will likely prove to be useful in future
studies of the natural history of SHV ESBLs.
MATERIALS AND METHODS
Bacterial isolates. The 21 isolates of K. pneumoniae used in this study were
isolated at the Princess Alexandra Hospital in Brisbane, Australia, and have been
previously characterized (6, 17). All strains were cultured in Luria-Bertani (LB)
broth and stored in cryovials with 12% glycerol at 80°C.
DNA extraction. DNA was extracted from 2.5-ml cultures grown overnight in
LB broth. For each isolate, 1 ml of culture was centrifuged for 2 min at room
temperature. The supernatant was discarded, and the pellet was washed twice in
TE buffer (10 mM Tris, 1 mM EDTA [pH 8.0]). The pellet was then resuspended
in 500 l of TE buffer and boiled for 20 min. The lysed cells were then centri-
fuged for 2 min, and the supernatant was removed and stored at 20°C.
Detection of mutations in bla genes by kinetic PCR. All reactions were per-
formed with an ABI Prism 7000 real-time PCR device (Applied Biosystems).
Allele-specific PCR primers were designed to interrogate single-nucleotide poly-
morphisms (SNPs) within the blaSHV gene. PCR was performed in 96-well
optical plates (Applied Biosystems) with a total reaction volume of 20 l. SYBR-
Green 1 2 master mix (Applied Biosystems) was used for all reactions, with 5
pmol of common primer, 5 pmol of either the wild-type-specific primer or
mutant-specific primer, and 1 l of bacterial cell lysate. The thermocycling
parameters were as follows: an initial denaturation step of 95°C for 60 s, 40 cycles
of denaturation at 94°C for 15 s, primer annealing at 60°C for 20 s, and extension
and optical read at 72°C for 30 s. The point at which the fluorescence reaches a
defined threshold defines a cycle number, called the CT value. The threshold for
each reaction plate was set in the logarithmic phase of amplification.
The sequence and annealing sites of allele-specific primers used are shown in
Table 1. All primers were designed by using Primer Express version 2.0 from
Applied Biosystems and have a theoretical melting temperature of 60°C. The
codon 238 SNP was interrogated by using Shv238mt and Shv238wt as the allele-
specific primers and Shv238 reverse as the common primer. The codon 240 SNP
was interrogated by using Shv240mt and Shv240wt as the allele-specific primers
and Shv240 reverse as the common primer.
Determination of sequence flanking the blaSHV gene in isolate I1. A gene
library of isolate I1 was constructed by using the  EMBL3 Packagene system
(Promega) in accordance with the manufacturer’s instructions. Resultant plaques
were transferred to nitrocellulose filters for screening with nucleic acid probes.
Digoxigenin (DIG)-labeled blaSHV PCR product was generated by using primer
set SHV-F/Shv238reverse (Table 1) with DIG-labeled deoxynucleoside triphos-
phate mix (Roche). Southern hybridizations with DIG-labeled PCR product
were then performed by using the DIG Easy Hyb kit (Roche), anti-DIG antibody
(Roche), and CDP-star (Roche) according to the manufacturer’s instructions.
Hybridizing plaques were selected, and lysate preparations were made by the
liquid culture method (16). Recombinant  DNA was isolated by a miniprep
procedure according to the instructions for the  EMBL Packagene system
(Promega). Purified recombinant  was restriction digested with SalI, BamHI,
and EcoRI and subjected to double digestion with SalI-BamHI, SalI-EcoRI, and
BamHI/EcoRI. Restriction digests were subject to gel electrophoresis with a
0.7% agarose gel and Tris-borate-EDTA buffer (40 V for 20 h). The gels were
then transferred to nylon membranes (16) and probed with DIG-labeled blaSHV.
Restriction fragments that contained sequence complementary to the blaSHV
probe and were of suitable size for cloning and sequencing were cloned into
appropriately digested pBlueScriptII. White colonies were selected and grown
overnight in LB-ampicillin broth, and the recombinant plasmid was purified by
the alkaline lysis plasmid miniprep procedure (16). The recombinant plasmid
inserts were then sequenced by using primer-walking methods. The complete
insert sequences were compared to all known sequences by using the BLASTn
program (National Center for Biotechnology Information).
Cloning and analysis of blaSHV genes and gene fragments. PCR amplicons
were generated from isolates B2, K2, J3, D1, L1, A1, J2, and I1 by using primer
sets that amplify all blaSHV variants (SHV-F/Shv238reverse) and primer se-
quences that amplify the 5 end of blaSHV together with upstream flanking
sequence (Pr-F/Shv238reverse and Pr::IS26-F/Shv238reverse) (Table 1). Ampli-
fication products were cloned by using the pGEM-T Easy plasmid kit (Promega)
and JM109 high-efficiency electrocompetent Escherichia coli cells prepared as
described by Sambrook and Russell (16). Twenty clones were selected for each
strain, and plasmid miniprep isolations were carried out for use in subsequent
sequencing and real-time PCR interrogation analysis. Plasmid miniprep solu-
tions diluted 400-fold were used as templates for analysis of the codon 238 and
codon 240 polymorphic sites. This was done by kinetic PCR with the method
described above.
Sequence determination. Cloned plasmid DNA was purified by using QIA-
quick miniprep kits (QIAGEN), and plasmid DNA was quantified by UV spec-
trophotometry. Plasmid DNA (200 to 500 ng) was sequenced by using 3.2 pmol
of the appropriate primer. Sequencing was performed at the Australian Genome
Research Facility, University of Queensland, Brisbane, Australia.
Relative quantitation by real-time PCR. Real-time PCR was used to deter-
mine the interisolate relative copy numbers of total blaSHV and also blaSHV in cis
with different flanking sequences. The comparative CT method (ABI PRISM
7000 sequence detection system user bulletin 2; Applied Biosystems) was used
with the 16S RNA-encoding gene as the standard. All measurements were
carried out in triplicate. The procedure was validated by making a twofold
dilution of the genomic preparation from isolate I1 and determining that for all
four primer sets the slopes of CT versus log dilution fell between 0.1 and 0.1.
TABLE 1. Primers for kinetic and relative quantitation PCR.
Primer name Gene Annealing region Primer sequence (533)a
16sAllBactF 16s rRNA () 1297/1318 TCCATGAAGTCGGAATCGCTAG
16sAllBactR 16s rRNA () 1374/1392 CACTCCCATGGTGTGACGG
SHV-F blaSHV () 310/327 TCAGCGAAAAACACCTTG
Pr-F pNSF-1b () 107/82 GATGAAGGAAAAAAGAGGAATTGTGA
SHVquantF blaSHV () 730/748 TGCTTGGCCCGAATAACAA
SHVquantR blaSHV () 766/786 GCGTATCCCGCAGATAAATCA
Pr::IS26-F pMPA2ac () 158/141 CCGGCCTTTGAATGGGTT
Prquant-R blaSHV () 3/24 TAATACACAGGCGAATATAACGCATAAC
Shv238mt blaSHV () 680/699 CGCCGATAAGACCGGAGCTA
Shv238wt blaSHV () 680/699 CGCCGATAAGACCGGAGCTG
Shv238reverse blaSHV () 770/781 CGGCGTATCCCGCAGATAA
Shv240mt blaSHV () 702/716 GCGCGCACCCCGCTT
Shv240wt blaSHV () 702/716 GCGCGCACCCCGCTC
Shv240reverse blaSHV () 663/679 CCGGCGGGCTGGTTTAT
Shv35mt blaSHV () 70/91 AGCCGCTTGAGCAAATTAAACA
Shv35wt blaSHV () 70/91 AGCCGCTTGAGCAAATTAAACT
Shv35reverse blaSHV () 174/194 CATCATGGGAAAGCGTTCATC
a 3 terminal bases for allele-specific oligonucleotides are underlined.
b GenBank accession no. AF282921, as reported by Fortineau et al. (4).
c GenBank accession no. X84314, as reported by Nuesch-Inderbinen et al. (10).
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While the comparative CT method can be used to estimate the absolute ratio
between the copy numbers of the same target in different isolates, it cannot be
used to determine the absolute copy number ratio of different targets. The
approach taken to estimating this parameter was to assume that the total amount
of blaSHV in any given isolate is equal to the amount of blaSHV in cis with flanking
sequence 1 plus the amount of blaSHV in cis with flanking sequence 2 (see Results
and Discussion). The relative copy number data from different isolates were then
used to generate simultaneous equations, the solution of which provided an
estimation of the absolute copy number ratios of the different targets.
The primers used are shown in Table 1 and are fully specified in Results and
Discussion.
Typing by PFGE. The isolates were grown on Mueller-Hinton II agar at 37°C
for 24 h. A single colony from each isolate was then selected and grown in 3 ml
of Mueller-Hinton II broth at 37°C for 20 h with gentle agitation. The control
strain used for pulsed-field gel electrophoresis (PFGE) experiments was K.
pneumoniae ATCC 13883. DNA was extracted from isolates, digested with XbaI,
and subjected to PFGE with the GenePath group 6 reagent kit (Bio-Rad)
according to the manufacturer’s instructions.
RESULTS AND DISCUSSION
Interrogation of the codon 238 and 240 polymorphic sites
using kinetic PCR. The first aim of this study was to develop a
single-step real-time PCR method for interrogating the blaSHV
codon 238 and 240 polymorphisms. This was done to deter-
mine if the minisequencing-based relative copy number deter-
minations by Howard et al. (6) could be confirmed and to
facilitate experiments designed to elucidate the molecular ba-
sis for the allele copy number variations. The approach used
was allele-specific real-time PCR, which is also known as ki-
netic PCR (5). This exploits the reduced extension frequency
from a mismatched 3 end of a PCR primer. It is more inher-
ently robust than conventional, end-point-analyzed allele-spe-
cific PCR because it depends upon a difference between the
allele-specific reactions with respect to the thermocycle num-
ber at which amplimer is detectable (the CT) rather than a
difference between the amounts of amplimer in the allele-
specific reactions at the reaction end points. With equal copy
numbers of the two alleles, each amplification product should
reach a detectable level at the same CT value. If an unequal
amount of an allele is present, the difference in the cycle
number (or CT value) between the two amplification reac-
tions provides a measure of relative gene dosages of each
allele.
All 21 isolates were subjected to three real-time assays with
each allele-specific primer set, and the CT values and their
standard deviations were calculated (Table 2). It is clear that
the isolates may be divided into distinct clusters. There is a
discontinuity in the codon 238 results that separates the dou-
ble-disk synergy test (DDST)-negative isolates (CT of
	4.14) from the DDST-positive isolates (CT of
0.65). A
second discontinuity in the codon 240 results separates the
high-resistance (i.e., high drug MIC) DDST-positive isolates
(CT of 
2.46) from the low-resistance DDST-positive and
DDST-negative isolates (CT of 	5.91). In the case of the
high-resistance isolates (L1, J2, C1, J1, G1, L1, and H1), there
was a clear trend for the higher CT values to be associated
with the highest resistance, although the codon 240 CT for
TABLE 2. Kinetic PCR results
Isolatea
Phenotypic datab Kinetic PCRc at codon:
DDST
MIC (g/ml) 238 240
ATM CAZ CTX
CT CT CT CT
Mutant Wildtype Mean SD Mutant
Wild
type Mean SD
B2  0.03 0.13 0.03 22.0 16.0 4.9 1.22 25.1 17.7 6.6 0.82
K2  0.03 0.13 0.03 21.7 14.5 7.0 0.33 23.8 13.1 10.4 0.55
M1  0.03 0.13 0.03 24.1 18.2 6.8 0.71 28.7 20.1 7.3 2.67
K1  0.06 0.50 0.06 21.8 15.1 6.7 0.27 24.1 17.8 5.9 0.52
J5  0.06 0.50 0.13 24.6 16.1 8.0 1.68 22.3 13.1 9.1 0.39
J3  0.13 0.50 0.13 22.6 17.5 4.1 1.16 21.0 14.4 6.5 0.78
L2  0.13 0.25 0.25 26.4 17.2 8.3 1.30 24.1 15.0 8.5 1.01
J4  0.25 2.00 0.13 21.0 15.1 6.0 0.25 21.3 11.7 9.3 0.31
F2  0.25 0.5 0.5 16.4 17.9 1.3 0.50 24.7 13.6 10.6 0.75
A1  0.5 1 1 15.2 16.7 1.4 0.31 23.3 12.9 10.0 0.58
E1  0.5 1 1 15.9 19.2 2.2 1.23 24.8 13.7 9.7 1.39
B1  1 1 1 16.3 17.8 1.3 0.20 23.1 14.1 8.8 0.42
F1  1 1 1 15.2 16.6 1.4 0.28 22.0 13.3 9.0 0.76
D1  2 4 4 14.2 17.0 2.9 0.71 22.4 12.5 9.8 1.05
L1  32 32 1 15.3 16.4 1.5 0.46 15.0 13.7 0.9 0.43
J2  64 32 2 15.9 16.0 0.2 0.38 14.7 13.0 1.8 0.49
C1  64 64 4 16.1 16.0 0.7 0.48 14.9 18.4 4.1 0.68
J1  64 32 4 16.6 16.4 0.2 0.22 15.5 14.0 2.5 1.48
G1  128 128 16 12.9 15.2 2.7 0.37 11.7 14.5 2.8 0.19
I1  128 128 16 13.0 15.4 2.3 0.59 11.7 14.7 3.4 0.28
H1  128 128 128 11.6 14.3 2.7 0.47 10.6 14.8 3.9 0.45
a Designations are as in reference 6.
b The DDST and MIC data are from reference 17. The highest concentration tested when the isolates were characterized (17) was 128 g/ml, so some MICs may
be higher than this. ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime.
c Shown are data from single replicates of CT measurements from each isolate and the mean CT and associated standard deviation from all replicates.
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isolate C1 is unexpectedly high. Despite the result for isolate
C1, the correlation coefficient for these isolates for the log
MIC of aztreonam (chosen because of the greatest range)
versus the sum of the codon 238 and codon 240 CT values is
0.73. The results are entirely consistent with the previously
reported minisequencing data (5) and confirm that relation-
ship between blaSHV-12 copy numbers and resistance levels.
Direct determination of allele copy number ratios by anal-
ysis of cloned blaSHV PCR products. In order to provide addi-
tional confirmation that the kinetic PCR procedure provided a
true indication of the blaSHV allelic dosage within an isolate,
we carried out cloning and analysis of blaSHV PCR products
from isolates B2, K2, J3, A1, D1, J2, L1, and I1. blaSHV internal
sequences spanning codons 238 and 240 were amplified from
total cellular DNA. The amplified material was ligated to
pGEM-T and transformed into E. coli JM109. Initially, inserts
in five clones derived from each isolate in the total blaSHV PCR
group were sequenced and also subjected to the kinetic PCR
assays. Both methods clearly identified the same bases at the
codon 238 and 240 polymorphic sites, and it was concluded
that the real-time PCR procedure was suitable for screening of
more clones. Fifteen more clones from each isolate were an-
alyzed by this method.
The results of clone interrogation are shown in Table 3.
These are consistent with the data in Table 2. Isolates B2, K2,
and J3 are DDST negative and, as expected, possessed no
mutant alleles. Isolate A1 is one of the lowest-resistance
DDST-positive isolates and, as expected, had a high propor-
tion of wild-type alleles and no double-mutant alleles. Isolate
D1 has a slightly higher level of resistance than A1, and, con-
sistent with this, a lower proportion of wild-type clones were
recovered. Interestingly, this isolate also yielded a small num-
ber of double-mutation clones, despite having an intermediate
resistance phenotype. Isolate J2 is at the low-resistance end of
the group of isolates that have previously been shown to pos-
sess the double mutation. This isolate did not yield any clones
of the single-mutation allele. Rather, the majority of clones
were wild type and a substantial minority were of the double-
mutation allele. Although this result was somewhat unex-
pected, it is consistent with both the high-resistance phenotype
and also the significantly negative CT value obtained from the
interrogation of the codon 238 mutation site (Table 4). Isolate
L1 has a resistance phenotype similar to that of J2. The dis-
tribution of clones is also similar, with the only differences
being a slightly lower proportion of wild-type alleles and the
presence of a small number of single-mutation alleles. Finally,
isolate I1 has one of the highest-resistance phenotypes. As
expected, the majority of the clones recovered were of the
double-mutation allele. These data confirmed that there is a
TABLE 3. blaSHV allele distributions found in a diverse subset of
isolates, as determined by analysis of cloned PCR products
Isolate
% blaSHV allelesa
238-G, 240-E 238-S, 240-E 238-S, 240-K
B2 100
K2 100
J3 100
D1 25 65 10
L1 60 5 35
A1 50 50
J2 80 20
I1 10 25 65
a The deduced gene products are shown.
TABLE 4. Relative quantitations of total blaSHV and blaSHV in cis with the different promoters and PFGE
Isolate DDST
MIC (g/ml)a Mean copy number (range)
Pulsotype
ATM CAZ CTX blaSHV pr::IS26-blaSHV pr-blaSHV
B2  0.03 0.13 0.03 0.396 (0.356–0.440) Nilb 0.082 (0.075–0.090) D
K2  0.03 0.13 0.03 1.00 (0.929–1.076) 0.897 (0.783–1.028) 0.102 (0.089–0.117) A
M1  0.03 0.13 0.03 0.444 (0.360–0.548) Nil 0.128 (0.102–0.161) C
K1  0.06 0.5 0.06 0.331 (0.302–0.363) Nil 0.178 (0.150–0.211) B
J5  0.06 0.5 0.13 0.696 (0.627–0.773) 0.417 (0.395–0.441) 0.175 (0.163–0.188) A4
J3  0.13 0.5 0.13 0.289 (0.258–0.324) Nil 0.197 (0.161–0.242) A2
L2  0.13 0.25 0.25 0.395 (0.303–0.515) Nil 0.124 (0.101–1.53) A5
J4  0.25 2 0.13 1.875 (1.657–2.122) 1.986 (1.642–2.402) 0.072 (0.053–0.96) A2
F2  0.25 0.5 0.5 0.785 (0.643–0.958) 0.313 (0.294–0.332) 0.099 (0.094–0.105) A
A1  0.5 1 1 0.794 (0.716–0.879) 0.433 (0.391–0.480) 0.189 (0.160–0.224) A
E1  0.5 1 1 0.664 (0.570–0.774) 0.613 (0.503–0.746) 0.197 (0.138–0.282) A6
B1  1 1 1 0.655 (0.547–0.785) 0.427 (0.384–0.475) 0.150 (0.132–0.172) A5
F1  1 1 1 0.707 (0.661–0.757) 0.369 (0.307–0.445) 0.084 (0.068–0.105) A
D1  2 4 4 1.701 (1.556–1.860) 1.721 (1.490–1.987) 0.085 (0.069–0.104) A1
L1  32 32 1 0.809 (0.689–0.949) 0.319 (0.254–0.400) 0.087 (0.079–0.096) A
J2  64 32 2 1.692 (1.552–1.848) 1.277 (1.064–1.533) 0.060 (0.018–0.206) A5
C1  64 64 4 0.835 (0.752–0.927) 0.613 (0.508–0.739) 0.133 (0.114–0.155) B
J1  64 32 4 0.968 (0.793–1.182) 1.32 (1.16–1.51) 0.124 (0.092–0.167) A3
G1  128 128 16 2.955 (2.498–3.496) 3.854 (3.418–4.347) 0.158 (0.122–0.206) A
I1  128 128 16 4.616 (4.203–5.070) 5.241 (4.863–5.648) 0.093 (0.086–0.102) A
H1  128 128 128 8.244 (7.628–8.909) 8.111 (6.776–9.709) 0.124 (0.102–0.150) A1
a ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime.
b On occasion, amplimer appeared very late in the cycling protocol, i.e., at least seven cycles later than for the isolates with measurable pr::IS26-blaSHV. This was
not reproducible (i.e., on most occasions the PCRs were entirely negative) and was probably due to contamination.
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correlation between relative allele copy numbers and resis-
tance phenotypes. In addition, they reveal a complex pattern of
variation from isolate to isolate and suggest that different
mixes of alleles can, on occasion, give rise to similar resistance
levels.
Characterization of sequences flanking blaSHV in isolate I1.
To further understand the molecular basis for the coexistence
of different blaSHV alleles, sequences upstream from blaSHV
were cloned and characterized. Isolate I1 was selected, as this
isolate is DDST positive and highly resistant. To avoid pre-
judging the nature of the upstream sequences, a cloning-based
approach (as opposed to PCR) was used. A EMBL3 library of
partially Sau3A-cleaved DNA was constructed and screened by
plaque hybridization with a blaSHV-derived probe. Two hybrid-
izing plaques, I1-3 and I1-9, were isolated, and their ge-
nomes were purified. Restriction analysis revealed that the
inserts were 22 to 24 kb in size. There was no discernible
overlap; i.e., there was no commonality of restriction frag-
ments. Southern hybridization indicated that both inserts carry
blaSHV and confirmed that the two inserts represent different
genetic environments for blaSHV. Hybridizing fragments were
subcloned and sequenced and were found to be identical to the
two previously described blaSHV promoter regions. The cloned
fragment from I1-9 was found to contain an IS26 element
insertion next to the 10 upstream region, as has been re-
ported for plasmid pMPA2a (10, 14). The cloned fragment
from I1-3 did not contain an IS26 element and was homolo-
gous to the prototype SHV-1 upstream region (14, 15). In the
interests of clarity, we have termed the two promoter regions
in cis with blaSHV, pr::IS26-blaSHV and pr-blaSHV (Fig. 1). The
genomes of an additional eight hybridizing phage were sub-
jected to restriction analysis, and they were all identical to
I1-3.
Interisolate relative copy numbers of blashv variants. The
results described to this point show that the level of resistance
is a function of the gene dosage of blaSHV mutant alleles.
However, given that we had found that blaSHV genes can exist
in two different genetic environments in individual isolates, it
was of interest to know whether the genetic environment dic-
tates the likelihood that a blaSHV gene will confer a high level
of resistance. Accordingly, the strategy for the remainder of
this study was to use real-time PCR to determine the interiso-
late relative copy numbers of total blaSHV and also blaSHV in
cis with the two different promoters and to use cloning and
analysis of PCR products to determine the distributions of
blaSHV alleles located in cis with the different promoters in a
subset of isolates.
The real-time PCR primers used are shown in Table 1. The
16S RNA-encoding genes were amplified by using primers
16sAllBactF and 16sAllBactR. Total blaSHV was measured by
using SHVquant and SHVquantR. pr::IS26-blaSHV was mea-
sured by using Pr::IS26-F and Prquant-R. pr-blaSHV was mea-
sured by using Pr-F and Prquant-R.
In order to meaningfully measure relative copy numbers by
using real-time PCR, several normalization steps were re-
quired. In summary, the 16S RNA-encoding gene was chosen
as the reference point to control for variability in the genome
extraction efficiencies, and isolate K2 was selected to be the
calibrator isolate. The quantity of each target in each isolate
was expressed as the difference in CT between the 16S RNA
FIG. 1. pr::IS26-blaSHV (A) and pr-blaSHV (B). Identical sequences in the promoter regions are underlined with dotted lines. The
pr::IS26-blaSHV cassette contains the IS26 element inserted next to the 10 region (15). The pr-blaSHV cassette does not contain IS26 element and
is identical to the prototype SHV-1 upstream region (15).
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gene and the target. The interisolate copy number ratios were
then calculated from the difference between these CT values
for the different isolates. At this point the data were normal-
ized such that the quantity of each target in the calibrator
isolate was 1. To provide an approximate indication of the
relative copy numbers of different targets within individual
isolates, the data were analyzed further. This was accomplished
by solving simultaneous equations derived from the data from
isolates K2 and H1, which were chosen because they spanned
a wide range of pr::IS26-blaSHV copy numbers. These equa-
tions stated that, for both of these isolates, the copy number of
the total blaSHV equaled the copy number of pr-blaSHV plus
pr::IS26-blaSHV. The solution to these equations was that in
isolate K2 there are 8.8 times more copies of pr::IS26-blaSHV
than there are of pr-blaSHV. This value was then used to nor-
malize the copy numbers of the other targets in all of the other
isolates, and this is what is shown in Table 4.
It would be expected that the pr-blaSHV copy number plus
the pr::IS26-blaSHV copy number equals the total blaSHV copy
number for all of the isolates. If this were not the case, then
either the copy number determinations did not provide mean-
ingful results and/or blaSHV exists in cis with an undiscovered
flanking sequence. Therefore, the correlation between total
blaSHV and pr-blaSHV plus pr::IS26-blaSHV was determined
(Fig. 2). A linear relationship exists between these two inde-
pendently determined parameters; the slope of the line ap-
proximates to 1, and the intercept is close to the origin. This
demonstrates that the interisolate copy number variations are
not experimental artifacts and essentially rules out the possi-
bility that the blaSHV gene exists with an undetected different
upstream sequence in any of these isolates.
It can be seen in Table 4 that pr-blaSHV displays very little
copy number variation and is present in all isolates, while
pr::IS26-blaSHV is not universally present and displays consid-
erable copy number variation. Also, the isolates with the high-
est resistance levels possessed the highest copy numbers of
pr::IS26-blaSHV. These data confirm the relationship between
copy number and resistance levels and suggest that pr::IS26-
blaSHV is plasmid borne while pr-blaSHV is located either on
the chromosome or on a plasmid with very tight copy number
control.
PFGE analysis of isolates. Interpretation of DNA restriction
patterns generated by PFGE was performed as described by
Tenover et al. (18). There was an apparent association between
pulsotype A and the pr::IS26-blaSHV cassette. All except one of
the non-pulsotype A isolates (C1) were negative for this cas-
sette, while all except two of the pulsotype A isolates (J3 and
L2) carried this cassette (Table 4). The presence of pr::IS26-
blaSHV in the pulsotype B isolate C1 suggests that it is present
on a transmissible plasmid. However, without more detailed
analyses we cannot exclude the possibility of pr::IS26-blaSHV
being present on different plasmids in different isolates.
Direct determination of the allele copy number ratios of
pr-blaSHV and pr::IS26-blaSHV. In order to determine whether
homologous recombination has resulted in the blaSHV alleles
located on different replicons being in equilibrium within in-
dividual isolates, PCR products representing blaSHV in cis with
the different upstream sequences were cloned and analyzed. A
representative subset of isolates was used for this experiment,
and the results are shown in Table 5. It is clear that in all
isolates, pr-blaSHV is predominantly but not exclusively wild
type at codons 238 and 240, while the relative copy numbers for
FIG. 2. Linear regression analysis for blaSHV relative quantitation
measurements.
TABLE 5. blaSHV allele distributions found in cis with the different promoters in a diverse subset of isolates, as determined by analysis of the
cloned PCR products
Isolate
% pr::IS26-blaSHV allelesa % pr-blaSHV allelesa
35-L 35-Q 238-G,240-E
238-S,
240-E
238-S,
240-K 35-L 35-Q
238-G,
240-E
238-S,
240-E
238-S,
240-K
B2 NAb NA NA NA NA 100 95 5
K2 100 100 100 100
J3 NA NA NA NA NA 100 95 5
D1 100 5 90 5 100 95 5
L1 100 5 95 100 95 5
A1 100 100 100 95 5
J2 100 70 30 100 100
I1 100 0 5 95 100 85 15
a The deduced gene products are shown.
b NA, not applicable because this promoter is absent from this isolate.
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the allelic variants of pr::IS26-blaSHV vary greatly. It may
therefore be concluded that the alleles are not in equilibrium
within individual isolates and that pr::IS26-blaSHV has the
dominant effect on the resistance phenotype, particularly in the
highly resistant isolates. Also of interest was the finding that all
sequences analyzed possessed the L35Q substitution that dif-
ferentiates SHV-1/2/5 from SHV-11/2a/12, irrespective of
whether they were derived from pr-blaSHV or pr::IS26-blaSHV.
The proportions of the different alleles are consistent with
the resistance phenotypes. The DDST-negative isolates B2 and
K2 have very few mutant alleles, the highly resistant J2 and L1
have high proportions of the double-mutant allele, and the
other intermediate-resistance isolates have intermediate allelic
contents. These data confirm that resistance levels are very
much a function of the copy numbers of mutant alleles. The
data also emphasise the generality of the coexistence of differ-
ent alleles in these isolates and clearly demonstrate that, de-
spite the effects of homologous recombination, the probability
that an individual blaSHV gene is mutated is a function of the
replicon on which the gene is located.
An unexpected aspect of these results was the detection of
unmutated pr::IS26-blaSHV, most particularly in isolates K2
and J2. This observation means that it is very unlikely that a
single plasmid with a mutated blaSHV was introduced into
southeast Queensland or the Princess Alexandra Hospital and
then underwent a dissemination process. Rather, the simplest
explanation is that a plasmid containing blaSHV-11 was extant,
and mutated derivatives of this were selected on one or more
occasions. If this is the case, then the low proportion of mutant
alleles of pr-blaSHV suggests that if an isolate has both
pr::IS26-blaSHV and pr-blaSHV and is subject to selection for
ESBL expression, then mutations in pr::IS26-blaSHV are more
likely to be evolutionarily fixed than mutations in pr-blaSHV. A
possible explanation for this is that a multicopy plasmid loca-
tion and/or the presence of IS26 in the promoter increase
expression and thus increase the impact upon the resistance
phenotype of the mutations that confer ESBL activity. It is
consistent with this hypothesis that all of the ESBL-positive
isolates in this study possessed pr::IS26-blaSHV.
Our results are similar to findings from studies on the dis-
tribution and genetics of SHV-2a and SHV-12 in Korea (8, 9).
These enzymes are the dominant ESBL SHV variants found in
that country, and it appears that their genes invariably possess
the promoter with the IS26 insertion (9). Those authors sug-
gested that the SHV-2a and SHV-12 enzymes arose from an
SHV-11 precursor whose gene also possessed the promoter
with the IS26 insertion. Our study has provided direct evidence
in support of this model, because we have detected blaSHV-11 in
cis with the IS26 promoter and have shown that it is present in
both ESBL-positive and ESBL-negative isolates. However, the
isolate-to-isolate variations in copy number of blaSHV-11 in cis
with the IS26 promoter do not support the conjecture of Kim
et al. (9) that the blaSHV-11 is chromosomally located and
distinct from the plasmid-located blaSHV-2a and blaSHV-12. En-
terobacteriaceae expressing SHV-12 have also been found to be
very widespread in Italy (12). It would be most interesting to
determine whether instances of wide dissemination of SHV-12
are always associated with IS26 insertions in the promoter.
Kim et al. (9) also postulated that the acquisition of the
point mutation that confers the L35Q substitution that defines
SHV-11, SHV-2a, and SHV-12 was coincident with the acqui-
sition of the IS26 insertion in the promoter. Our study has
demonstrated that this is not the case, as all cloned PCR
products that were fully sequenced contained the mutation,
irrespective of whether there was an IS26 insertion in the
promoter.
In conclusion, we have used a detailed study of a small
collection of geographically and temporally linked K. pneu-
moniae clinical isolates to illuminate aspects of the natural
history of blaSHV genes. This has revealed that a mix of alleles
in individual isolates is the norm rather than the exception and
that there is a strong relationship between high levels of resis-
tance and a high copy number of blaSHV-12. The most likely
mechanism for the acquisition of resistance in this collection is
the dissemination of a plasmid carrying blaSHV-11 followed by
one or more rounds of selection for the ESBL-positive mutants.
The apparent ability of a gene cassette consisting of IS26 and
blaSHV-11 to facilitate the appearance of resistance in response to
selection, even in the presence of a blaSHV gene with a different
promoter, may be of clinical significance. We are currently inves-
tigating the relationship between the presence of this cassette and
frequencies of mutation to an ESBL-positive phenotype.
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